- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06625034
Bestralingstherapie met op kennis gebaseerde planning van RapidPlan versus mensgestuurde planning voor de behandeling van prostaatkanker
Gerandomiseerd fase III-onderzoek naar op kennis gebaseerde planning op basis van een snel plan versus door de mens aangestuurde planning voor radiotherapie bij prostaatkanker
This phase III trial compares the effects of radiation therapy using RapidPlan, trademark, knowledge-based planning to human-driven planning in treating patients with prostate cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Successful delivery of radiation requires planning to develop a treatment plan for how and where the radiation is to be delivered. RapidPlan is a knowledge-based treatment planning tool that automatically creates an optimal treatment plan based on identified targets and organs at risk for radiation exposure. Human-driven treatment planning by a dosimetrist, the current standard of care, requires significant resources and time and may vary within and among radiation centers. Giving radiation therapy with RapidPlan knowledge-based planning may have similar or less side effects compared to human-driven planning in treating patients with prostate cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
- Procedure: Biospecimen Collection
- Procedure: Magnetic Resonance Imaging
- Ander: Questionnaire Administration
- Procedure: Positron Emission Tomography
- Straling: Photon Beam Radiation Therapy
- Straling: Radiation Therapy Treatment Planning and Simulation
- Straling: Radiation Therapy Treatment Planning and Simulation
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To determine if RapidPlan knowledge-based planning is non-inferior to human-driven planning regarding treatment-related rates of grade 3 or higher genitourinary (GU) and gastrointestinal (GI) adverse events at 3 months post-radiotherapy for prostate cancer.
EXPLORATORY OBJECTIVES:
I. After completion of radiation therapy, determine the incidence of:
Ia. Grade 2 or greater GU and GI toxicity at 3 months (Common Terminology Criteria for Adverse Events [CTCAE] version 5); Ib. Quality of life 3 months post-radiotherapy; Ic. Rate of achieving dose-volume constraints. II. Determine if there are any statistical differences in dose-volumes results with RapidPlan knowledge-based planning.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A (HUMAN-DRIVEN): Patients receive human-driven treatment planning and undergo radiation therapy over 15-30 minutes on 5-44 fractions per standard of care. Additionally, patients undergo magnetic resonance imaging (MRI) pre-treatment and blood sample collection and positron emission tomography (PET) throughout study.
ARM B (KNOWLEDGE-BASED): Patients receive RapidPlan treatment planning and undergo radiation therapy over 15-30 minutes on 5-44 fractions per standard of care. Additionally, patients undergo MRI pre-treatment and blood sample collection and PET throughout study.
After completion of study treatment, patients are followed up at 3 and 12 months then yearly for up to year 5.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Clinical Trials Referral Office
- Telefoonnummer: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
Studie Contact Back-up
- Naam: Cancer Clinical Trials Referral Office
- Telefoonnummer: 507-293-6386
Studie Locaties
-
-
Arizona
-
Scottsdale, Arizona, Verenigde Staten, 85259
- Werving
- Mayo Clinic in Arizona
-
Contact:
- Clinical Trials Referral Office
- Telefoonnummer: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Hoofdonderzoeker:
- Nathan Y. Yu, MD
-
Contact:
- Cancer Clinical Trials Referral Office
- Telefoonnummer: 507-293-6386
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224-9980
- Nog niet aan het werven
- Mayo Clinic in Florida
-
Contact:
- Clinical Trials Referral Office
- Telefoonnummer: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Contact:
- Cancer Clinical Trials Referral Office
- Telefoonnummer: 507-293-6386
-
Hoofdonderzoeker:
- Homan Mohammadi, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must be at least 18 years old
- Histologically confirmed prostate cancer
- Clinical or pathologic stages T1c-T3b, Nx or N0-1, M0-1 (American Joint Committee on Cancer [AJCC] criteria 8th edition [Ed])
- Planned definitive dose radiotherapy to the prostate or prostate bed
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 assessed within 90 days of enrollment
- Patients must sign Institutional Review Board (IRB) approved study specific informed consent
- Patients must complete all required pre-entry tests within the specified time frames
- Patients must be able to start treatment (radiation) within 180 days of study registration
- In case of confusion about the eligibility or ineligibility of an individual patient, the principal investigator (PI) can be used as the arbiter and a note to file will be added to the subject's regulatory binder to document outcome
Exclusion Criteria:
- Previous pelvic radiation > 5 Gy
- Planned delivery of radiotherapy to pelvic lymph nodes
- Planned delivery of brachytherapy of the prostate
- Active rectal diverticulitis, Crohn's disease affecting the rectum, or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed)
- Prior hip replacement or penile implant
- Major medical, addictive, or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (consent by legal authorized representative is not permitted for this study)
- Indwelling or intermittent urinary catheter use
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm A (human-driven treatment planning, radiation therapy)
Patients receive human-driven treatment planning and undergo radiation therapy over 15-30 minutes on 5-44 fractions per standard of care. Additionally, patients undergo MRI pre-treatment and blood sample collection and PET throughout study. |
Undergo blood sample collection
Andere namen:
Undergo MRI
Andere namen:
Ancillary studies Undergo PET
Andere namen:
Undergo radiation therapy
Andere namen:
Receive human-driven treatment planning
Andere namen:
Receive RapidPlan treatment planning
Andere namen:
|
|
Experimenteel: Arm B (RapidPlan treatment planning, radiation therapy)
Patients receive RapidPlan treatment planning and undergo radiation therapy over 15-30 minutes on 5-44 fractions per standard of care. Additionally, patients undergo MRI pre-treatment and blood sample collection and PET throughout study. |
Undergo blood sample collection
Andere namen:
Undergo MRI
Andere namen:
Ancillary studies Undergo PET
Andere namen:
Undergo radiation therapy
Andere namen:
Receive human-driven treatment planning
Andere namen:
Receive RapidPlan treatment planning
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of grade 3 or higher genitourinary (GU) and gastrointestinal (GI) adverse events (AEs)
Tijdsspanne: Up to 3 months post-radiotherapy
|
AEs will be defined using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Comparisons between treatment arms will be made using a non-inferiority test for the difference between two proportions with an alpha level of 5%. The proportion of patients experiencing grade 3 or higher GU or GI AEs over the number of patients eligible for toxicity will be estimated. |
Up to 3 months post-radiotherapy
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Nathan Y. Yu, MD, Mayo Clinic
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Genitale neoplasmata, mannelijk
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Genitale ziekten, man
- Prostaat Ziekten
- Mannelijke urogenitale ziekten
- Prostaatneoplasmata
- Onderzoekstechnieken
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Fysieke fenomeen
- Chemie -technieken, analytisch
- Spectrumanalyse
- Elektromagnetische fenomenen
- Magnetische fenomenen
- Elektromagnetische straling
- Elementaire deeltjes
- Licht
- Optische fenomenen
- Straling, niet -ionisatie
- Bestraling
- Exemplaarbehandeling
- Magnetische resonantiespectroscopie
- Fotonen
Andere studie-ID-nummers
- GMROA2451
- GMROA2451 (Andere identificatie: Mayo Clinic Radiation Oncology)
- NCI-2024-07870 (Register-ID: CTRP (Clinical Trial Reporting Program))
- 24-006449 (Andere identificatie: Mayo Clinic Institutional Review Board)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .